Covid-19 is pushing pharma companies to the cloud
The Covid-19 pandemic has rapidly accelerated the drug industry’s migration to the cloud, with pharma striking new deals with tech giants.
Related Articles
Medicare official says breakthrough device reimbursement rule coming in early summer
The federal agency has faced intense pressure from device makers frustrated with the slow pace of Medicare reimbursement decisions.
How AI can help satisfy FDA’s drug, device diversity requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.
Moving the conversation about obesity beyond the scale
Millions of Americans struggling with obesity need ways to lose weight that benefit the body as a whole, not just whittle away body fat.
Listen: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
This week on “The Readout LOUD” podcast: How does a startup compete in the rapidly evolving field of weight loss drugs? And how did a…
Covid ignited a global controversy over what is an airborne disease. The WHO just expanded its definition
A WHO advisory committee outlined a new set of definitions that more accurately reflect the science of airborne disease transmission.
Microsoft is selling AI in health care, and helping to set its standards. Is that a problem?
For some, Microsoft’s deep involvement in setting standards for the use of AI in health care raises questions about “regulatory capture.”
Elevance’s private equity deal will form $4 billion primary care company
Health insurer Elevance’s private equity deal will form a $4 billion primary care company.
Health disparities and premature deaths run deep, even in best-performing states
A new analysis of health inequities shows that every state has deep racial and ethnic disparities in the performance of their health care systems.
Chuck Schumer’s broken promise on affordable insulin
For more than two years, Sen. Chuck Schumer has been promising to hold a vote to make insulin affordable for people with all types of…
Dana-Farber retracts string of studies in systematic review of data integrity
“It is good to see this institution taking a harder stance against sloppy science and intentional data falsification that many institutes have done in the…